FDA Turns Down Sensor-Embedded Tablet For Monitoring Medication Adherence

The agency says it needs more information, and especially more usability testing, before it can approve a new drug application on a combination product that integrates Otsuka’s Abilify antipsychotic with an ingestible sensor made by Proteus, intended to improve medication adherence.

More from Archive

More from Medtech Insight